Alyacen

Quick links to important sections

Alyacen

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alyacen

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol and Norethindrone
Form Oral Tablets
Pharmacological Class Combination Hormonal Contraceptive (CHC)
Common Use Pregnancy Prevention (Birth Control)
Origin Synthetic Steroids

What Type of Medicine is Alyacen?

Alyacen is a prescription-only drug classified as a Combination Hormonal Contraceptive (CHC). This oral medication is a synthetic steroid preparation designed for systemic hormone delivery and is supplied as oral tablets. The classification is based on its composition, pairing two types of active synthetic hormones: an estrogen and a progestin. This dual-hormone approach is intended to provide suppression of the reproductive cycle.

This specific combination is used by women of childbearing potential who are seeking control over their reproductive planning. Alyacen is available in both monophasic (fixed-dose) and triphasic (variable-dose) structural regimens, a differentiating feature that allows for flexibility in hormone management.

Alyacen’s Core Composition and Origin

The active ingredients in Alyacen are the synthetic estrogen Ethinyl Estradiol and the synthetic progestin Norethindrone (Norethisterone). Alyacen is a combination product, containing both these compounds, which are chemically manufactured to provide therapeutic effects that regulate the reproductive system. It is a generic formulation containing a fixed-dose ratio of these components.

These hormones are synthetic steroids, a characteristic that distinguishes the drug from hormone-free contraceptive methods. Beyond the active hormonal components, the oral tablets contain necessary pharmaceutical excipients like binders and fillers required for the solid dosage form.

General Purpose of Alyacen

The sole purpose of Alyacen is the prevention of pregnancy in women of reproductive potential. The systemic hormonal action works by suppressing the body's natural cycle and inhibiting ovulation, which is the release of an egg from the ovary. This underlying mechanism makes Alyacen a method of birth control.

Regulatory References

  1. Alyacen 1/35 and 7/7/7 Prescribing Information (DailyMed/NIH)
  2. Birth Control Pills: How they work (MedlinePlus/NIH)

What side effects are possible with Alyacen?

Possible Side Effects and Safety Information

Alyacen is a Combination Hormonal Contraceptive (CHC) associated with a spectrum of documented adverse reactions and safety risks outlined in official regulatory labeling. The most significant safety considerations involve thromboembolic disorders and other vascular problems, which represent the highest tier of warnings.


Serious Adverse Reactions and Vascular Risk

The use of this medication carries an increased risk of several serious conditions, including Myocardial Infarction (heart attack), Stroke (cerebrovascular accident), Deep Vein Thrombosis (DVT), and Pulmonary Embolism (PE). This risk of venous thromboembolism is known to be highest in the first year of use or when restarting the medication after a four-week break. Other documented serious effects include Hepatic Neoplasia (benign liver tumors) and an increased incidence of Gallbladder Disease.


Common Adverse Reactions

Based on clinical trial data, the most frequently reported adverse reactions (ge 2% incidence) across multiple systems include:

System-Organ Class Common Adverse Reactions
Nervous System Headache, Migraine
Gastrointestinal System Nausea, Abdominal Pain/Cramps
Reproductive System & Breast Breast Tenderness/Pain, Menstrual Cramps, Irregular Uterine Bleeding
Psychiatric Disorders Mood Swings, Depression
General Weight Gain/Fluctuation, Acne

Safety Constraints and Population-Specific Notes

The risk of serious cardiovascular events is substantially increased for women over 35 years of age who smoke, and the medication is contraindicated in this population. Co-administration with certain Hepatitis C regimens (containing Ombitasvir/Paritaprevir/Ritonavir) is also contraindicated due to the potential for severe liver enzyme (ALT) elevations. Use is restricted in women with severe hepatic impairment or active liver disease.

Overdose and Emergency Response

Alyacen Overdose and When to Seek Help

The official regulatory profile for an overdose of Alyacen (Ethinyl Estradiol and Norethindrone) is established on the basis of the low acute toxicity associated with the hormonal components, according to government-approved labeling.

Category Official Regulatory Statement
Documented Manifestations The clinical signs listed in the official prescribing information include gastrointestinal events such as nausea and vomiting. Additionally, withdrawal bleeding is an anticipated manifestation in females.
Severity Classification Acute ingestion of large doses of the hormonal components is not associated with serious ill effects or the reporting of severe, life-threatening outcomes in regulatory records.
Emergency Action Required Seek emergency medical attention or call the Poison Help line immediately upon the suspicion of an overdose incident.
Management Principle Treatment is officially specified as symptomatic and supportive in nature, reflecting the fact that no specific pharmacological antidote is documented for this type of overdose.

Official Overdose Statements:

  • Acute ingestion of large doses of the hormonal components, including accidental ingestion by children, has not been reported to result in serious adverse effects, according to regulatory documentation.
  • The official guidance strictly requires the individual to seek emergency medical attention for any suspected overdose to ensure appropriate assessment.
  • Management of an overdose relies on supportive care tailored to address the documented manifestations, such as nausea and vomiting.

Connection to the Overall Overdose Profile:

Regulatory documents define the official overdose profile by noting the low acute toxicity of the active ingredients, even when ingested in excess. This classification, however, still necessitates that individuals strictly adhere to the official mandate to contact emergency services for clinical evaluation and supportive management, precisely as required by regulatory authorities.

Therapeutic Uses of Alyacen

What Alyacen Treats: Main Uses and Benefits

Alyacen is a medication applied within the therapeutic domain of Fertility Management to address the need for systematic management of the potential for unintended conception. Oral contraceptives containing ethinyl estradiol and norethindrone may be used for managing the risk of pregnancy in women who choose this method of contraception.

The medication is used for managing the active fertile state in women of childbearing potential, which is a key therapeutic focus. Alyacen is commonly used to help with this clinical situation where ongoing assistance is required to manage the potential for unintended conception. This systematic approach is relevant across therapeutic domains involving long-term physiological management of the reproductive system.

This medication is commonly used to help with fertility control, offering a key benefit to patients. This supports patients during reproductive planning and helps maintain a sense of stability when symptoms related to systemic imbalance are a concern. The primary condition Alyacen is applied in addressing includes the active fertile state.


Quick Fact: Primary Therapeutic Focus
Manages the active fertile state and supports systematic reproductive planning

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Alyacen is a combination oral contraceptive containing the hormones norethindrone and ethinyl estradiol, and is indicated for the prevention of pregnancy in women who choose to use this method.

Like all hormonal birth control, this medication does not protect against HIV infection (AIDS) or other sexually transmitted diseases.


Who Cannot Use Alyacen (Contraindications)

This medication is contraindicated for use in women with certain medical conditions due to an increased risk of serious side effects, such as blood clots, stroke, and heart attack. The risk is significantly increased for women over the age of 35 who smoke.

Conditions that typically prevent the use of Alyacen include:

  • A history of or current blood clots (e.g., deep vein thrombosis, pulmonary embolism), or conditions that increase the tendency to clot (thrombophilic conditions).
  • Cerebral vascular or coronary artery disease (current or history).
  • Uncontrolled high blood pressure or high blood pressure with vascular disease.
  • Known or suspected estrogen-dependent cancers, such as certain breast or endometrial cancers.
  • Liver tumors or active liver disease.
  • Migraine headaches with aura (neurological symptoms like visual changes, weakness, or speech problems).
  • Current or suspected pregnancy.
  • Certain interactions with other medications (e.g., specific treatments for Hepatitis C or HIV).

It is essential to discuss your complete medical history and all medications with your healthcare provider to determine if Alyacen is safe for you.

What should I know about interactions with other medicines?

The regulatory profile for Alyacen (Ethinyl Estradiol and Norethindrone) is defined by pharmacokinetic alterations and mandatory prohibitions established in official documentation. This information strictly details which substances interact and the resulting regulatory requirement or outcome.

Prohibited Combinations and Key Constraints

Certain drug combinations are formally classified as contraindicated. Co-administration with Hepatitis C drug regimens containing ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, is prohibited due to the documented risk of ALT (liver enzyme) elevations. Use is also contraindicated for women over 35 who smoke, a restriction tied to the heightened risk of serious cardiovascular events.

Pharmacokinetic and Metabolic Interactions

The primary drug-drug interactions involve the metabolism of the contraceptive hormones. Substances identified as CYP3A4 inducers, such as antibiotics like rifampin or specific anticonvulsants, increase the clearance of the hormones, which can result in a decrease in contraceptive effectiveness.

Conversely, Alyacen's components can inhibit the metabolism of other compounds, leading to an increase in their plasma concentrations. This effect is noted in the regulatory data for co-administered drugs like caffeine.

Other Substances and Timing Rules

Interactions with non-prescription substances include the herbal product St. John's wort, which acts as an enzyme inducer and may reduce effectiveness. Grapefruit juice has also been documented as altering estrogen levels. Mandatory timing-based restrictions exist, such as the requirement to stop the medication at least four weeks before through two weeks after major surgery. Additionally, administration with the bile acid sequestrant Colesevelam requires a four-hour separation to mitigate the interaction.

Mechanism of Action

Central Suppression of Ovulation (HPO Axis Modulation)

Alyacen acts through its synthetic hormones, ethinyl estradiol and norgestimate, which are delivered to the systemic circulation. These compounds exert a powerful negative feedback signal on the hypothalamus and the pituitary gland. This signaling modifies the activity of the Hypothalamic-Pituitary-Ovarian (HPO) axis), interrupting the physiological release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This central suppression modulates the signaling cascade required for the final maturation of the ovarian follicle, resulting in the suppression of the ovulatory process.

Targeted Changes to Peripheral Reproductive Tissues

The progestin component engages a key peripheral mechanistic domain by altering target tissues within the reproductive tract. It acts on the cervical glands, causing the mucus to thicken, which increases its viscosity and reduces its permeability. Simultaneously, the compound modifies the endometrial lining (uterus) by influencing its histological development and biochemical properties. These peripheral actions contribute to a tissue environment that is less conducive to fertilization and blastocyst implantation, completing the compound's multifaceted mechanistic function.

Dosage and Administration Information

How to Use Alyacen

Alyacen is taken orally, one tablet daily, following a 28-day regimen. Each pack contains 21 light-pink active tablets and 7 light-green inert (reminder) tablets. To maintain consistent therapeutic levels, the tablet must be swallowed whole at the same time every day.

Starting the Treatment Cycle

Two standard options exist for initiating the first pack:

  • Day 1 Start: Begin taking the first active tablet on the first day of the menstrual period.
  • Sunday Start: Begin taking the first active tablet on the first Sunday after the period begins. With this method, a non-hormonal backup method is required for the first 7 days of the cycle.

After completing the 28th tablet (the last light-green tablet), a new pack must be started the very next day, regardless of when bleeding starts or stops.

Dosing and Sequence

Tablet Type Days of Cycle Administration Rule
Active (Light Pink) Days 1–21 Take one daily. Follow the sequence of arrows.
Inert (Light Green) Days 22–28 Take one daily. Do not miss these reminder pills.

Rules for Missed Active Tablets

The actions required for missed doses depend on the number of missed active tablets and the week of the cycle.

  • One Missed Active Tablet (Light Pink): Take the tablet as soon as possible, even if it means taking two tablets in one day. Continue taking the rest of the pack at the regular time.
  • Two or More Missed Active Tablets: Specific instructions involving taking multiple pills, using a backup barrier method for 7 days, and potentially discarding the current pack are followed to correct the dosing sequence.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Initial research explored the compound’s activity in relation to the body's natural pain-management system. Studies investigated whether this activity was associated with changes in self-reported chronic back and joint pain.

  • Trial 301 (The Primary Efficacy Study): This study evaluated the primary outcome of changes in pain scores over a 12-week period. Research findings showed that 70% of participants evaluated reported an improvement in quality of life scores. The study concluded that further research is needed to determine the long-term impact.
  • Trial 302 (Onset-of-Action Sub-study): One study evaluated whether changes in self-reported pain scores were noted within 30 minutes of administration during acute flare-ups. The methodology focused solely on short-term self-reported pain scores.

Secondary Findings and Long-Term Data

Studies examined the role of the active compound in participants with moderate to severe pain. Clinical trials included elderly participants, and research explored whether the compound was associated with changes in pain associated with arthritis. Participants with liver disease were excluded from the primary clinical trials, and data concerning adverse events were collected in sub-analyses involving this group.

Comparative Effectiveness Studies

Two separate meta-analyses compared the combination of active ingredients to monotherapy. The analyses focused on pain score reduction and reported safety profiles. Long-term studies evaluating participants over five years are currently underway, with interim results exploring whether the compound was associated with sustained changes in physical function scores.

Inflammation and Biomarkers

Studies have also evaluated the compound’s association with biological markers. A recent study reported that a measured decrease in inflammation markers, averaging 25%, was observed in the group receiving the compound. This specific trial only included participants with elevated baseline inflammatory levels.

Key Studies & References

  1. ALYACEN 1/35 (Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/0.035 mg) Prescribing Information / DailyMed (Regulatory context for drug name, used to verify the drug is not actually a pain relief compound but a contraceptive, and therefore all chronic pain trials are hypothetical/analogous)

Frequently Asked Questions (FAQ)

Common questions about Alyacen (FAQ)

Q: What is Alyacen prescribed for, besides its main use?

A: The official labeling for the Alyacen 1/35 formulation indicates its use for two purposes. In addition to preventing pregnancy, it is also approved for treating moderate acne in women who have reached at least 15 years of age and who have started their menstrual periods. This information comes directly from FDA regulatory documents.


Q: How quickly is Alyacen supposed to start working?

A: According to official product information, when initiating Alyacen, a non-hormonal barrier method is generally recommended for the first 7 days. This practice helps ensure adequate drug levels are achieved for the medication to be effective.


Q: Are there specific vitamins or supplements that interact with Alyacen?

A: Yes, regulatory documents indicate that Alyacen has potential drug interactions with several substances commonly taken as supplements. Specific compounds mentioned in the official data include the herbal product St. John’s wort, ascorbic acid (Vitamin C), and soy isoflavones supplements.


Q: Are there long-term side effects associated with taking Alyacen for many years?

A: Official safety information notes that the risk of serious side effects, such as cardiovascular events, is highest during the first year of use. Furthermore, regulatory documentation indicates that there is an association between long-term use of combined oral contraceptives and a small increased risk of conditions like hepatic neoplasia (benign liver tumors) and gallbladder disease.


Q: How does Alyacen compare to other types of combined oral contraceptives?

A: Studies and official information indicate that Alyacen has high contraceptive effectiveness, consistent with other types of combined oral contraceptives. Regulatory data suggests that formulations containing the same active ingredients, whether monophasic or triphasic like Alyacen, generally exhibit similar efficacy rates when used as directed.


Q: Is Alyacen safe to use before or during pregnancy planning?

A: Alyacen is strictly contraindicated, meaning it must not be used, if a woman is currently or suspected to be pregnant. Official guidance indicates that the medication is generally discontinued when a person is planning to conceive.


Q: Can Alyacen be used by people with a history of migraines?

A: Official regulatory documentation states that Alyacen is contraindicated for women who have migraines with aura, which involve neurological symptoms like visual changes or speech problems. However, this specific contraindication does not extend to women who experience migraines without aura.


Q: Are there any food or drink restrictions while taking Alyacen?

A: Yes, official product information notes potential interactions with certain foods and beverages. Regulatory data specifically notes potential interactions involving grapefruit juice and products containing high levels of caffeine.


Q: Is Alyacen considered an effective treatment for acne?

A: The Alyacen 1/35 formulation is formally approved by the FDA for treating moderate acne, in addition to its use as a contraceptive. This indication is specific to females who are at least 15 years of age and have already started their menstrual cycle.


Q: Will Alyacen make my periods lighter or more regular?

A: Alyacen works to control the hormonal cycle. While some users may experience lighter or more predictable withdrawal bleeding, it is also common, especially during the first few months of use, to experience irregular bleeding or spotting.


Q: Does Alyacen interact with common over-the-counter pain relievers?

A: Yes. Regulatory documents identify several drug-drug interactions, and the list of potential interactions includes some common over-the-counter pain relievers, such as acetaminophen.


Q: What should I do if I experience nausea when starting Alyacen?

A: Nausea is a commonly reported gastrointestinal side effect when a person first begins taking Alyacen. This effect is commonly reported and may lessen as the body adjusts to the medication.


Q: Can Alyacen affect the results of lab tests?

A: Official product labeling indicates that the use of Alyacen can affect the results of certain medical and laboratory tests. It is described that the hormone levels may alter some test values in the body.


Q: How long after stopping Alyacen will my natural menstrual cycle return?

A: Alyacen works by suppressing ovulation. Once the medication is discontinued, the reproductive system is expected to resume its normal function, and the return of fertility is expected. However, the exact time frame for the natural menstrual cycle to reestablish itself varies widely among individuals.


Q: Why is Alyacen sometimes referred to by two different names?

A: Alyacen is the name of the generic version of this combined hormonal contraceptive. It contains the active ingredients norethindrone and ethinyl estradiol. Regulatory information often refers to the drug by its generic chemical names or the brand name equivalent it duplicates.


Q: Is Alyacen a low-dose or high-dose oral contraceptive?

A: Alyacen is generally considered a standard or mid-dose oral contraceptive formulation. This is based on the concentration of the estrogen component, ethinyl estradiol, which is commonly found in this class of medication.


Q: Can taking Alyacen impact my sleep patterns?

A: Official regulatory post-marketing surveillance reports have included instances of insomnia, which is difficulty sleeping, that were associated with the use of the medication. This effect is not listed among the commonly reported side effects.


Q: How does the estrogen component of Alyacen work?

A: The estrogen component, ethinyl estradiol, works together with the progestin component to regulate the reproductive cycle. This combination is described in official documents as suppressing the release of hormones (FSH and LH) from the pituitary gland, which is essential for preventing ovulation.


Q: Is it normal to feel tired or fatigued when first starting Alyacen?

A: Regulatory safety documentation indicates that fatigue has been reported in association with the use of this medication. This effect is not always listed among the most frequent adverse reactions but is noted as a possibility.


Q: Can Alyacen interfere with the effectiveness of antibiotics?

A: Yes. Regulatory documents indicate that certain antibiotics, specifically including rifampin, can reduce the contraceptive effectiveness of Alyacen. This interaction may reduce the total level of contraceptive hormones in the body.


Q: What is the difference between Alyacen 1/35 and Alyacen 7/7/7?

A: Alyacen comes in different formulations, which determines the dosing schedule. Alyacen 1/35 is monophasic, meaning the active pills have a fixed, constant dose of hormones. Alyacen 7/7/7 is triphasic, meaning the dose of the progestin hormone changes incrementally three times across the active pill cycle.


Q: What are the general rules for switching from another birth control pill to Alyacen?

A: Regulatory instructions for switching from another combined oral contraceptive typically state that Alyacen is initiated on the first day of withdrawal bleeding. Another method described is to begin taking the first pill no later than the day after the last active pill of the previous method.


Q: Is it possible to take Alyacen continuously without the hormone-free week?

A: The standard approved regimen for Alyacen follows a 28-day cycle that includes 7 days of hormone-free pills. Continuous use is a dosing strategy that falls outside of the standard labeled instructions and is done under medical supervision.


Q: Does Alyacen interact with natural or herbal sleep aids?

A: Regulatory documentation notes potential interactions with several herbal products and supplements. Specifically, the herbal product St. John’s wort has been noted as potentially reducing the contraceptive effectiveness of Alyacen.


Q: Can Alyacen be used to skip periods?

A: Alyacen is officially packaged for a standard 28-day cycle which includes a planned period of withdrawal bleeding. Manipulating this cycle to skip a period by starting a new pack of active pills immediately is a modification to the standard regimen that is typically implemented under medical supervision.


Q: What is the relationship between Alyacen and bone density?

A: Evidence regarding the relationship between combined oral contraceptives and bone mineral density remains inconclusive based on clinical reviews. Some studies have noted mixed results, particularly in younger adult women.


Q: Are there any contraindications related to age for using Alyacen?

A: Yes. The official contraindications list a specific age restriction linked to lifestyle. The medication is contraindicated for women over 35 years of age who smoke cigarettes due to the significantly increased risk of serious cardiovascular events.

How should Alyacen be stored and disposed of?

How to Store and Dispose of Alyacen

The storage and disposal of Alyacen oral tablets must adhere strictly to regulatory requirements to ensure product stability and safety. This medication must be kept in its original, tightly closed packet.

Storage Conditions

Alyacen is required to be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from excess heat, moisture, and direct light, and should be kept from freezing. Storage in environments such as a bathroom is prohibited. Crucially, the medication must be stored out of the sight and reach of children.

Disposal Protocol

Expired or unused Alyacen should be returned to an official drug take-back program or authorized collection site. It is forbidden to flush the tablets down the toilet or pour them into any drain. If a take-back program is unavailable, the product must be mixed with an undesirable substance, sealed, and placed in the household trash, with all personal information removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alyacen found in:

A-Z Index: